aTyr Stock Is Buoyant On Highly-Promising Lung Disease Data – Wait For Hype To Die Down And Buy
SolStock/E+ via Getty Images
Investment Thesis
Fibrosis has proven to be an elusive target for drug developers, so when a largely unheralded biotech delivers a promising set of clinical trial data, using a drug with a novel mechanism of action, there’s…
